全文获取类型
收费全文 | 317805篇 |
免费 | 19167篇 |
国内免费 | 474篇 |
专业分类
耳鼻咽喉 | 4425篇 |
儿科学 | 11152篇 |
妇产科学 | 10998篇 |
基础医学 | 47766篇 |
口腔科学 | 7726篇 |
临床医学 | 27016篇 |
内科学 | 59526篇 |
皮肤病学 | 6813篇 |
神经病学 | 23187篇 |
特种医学 | 12040篇 |
外国民族医学 | 43篇 |
外科学 | 48894篇 |
综合类 | 8001篇 |
现状与发展 | 1篇 |
一般理论 | 196篇 |
预防医学 | 23036篇 |
眼科学 | 7239篇 |
药学 | 22292篇 |
中国医学 | 808篇 |
肿瘤学 | 16287篇 |
出版年
2021年 | 2974篇 |
2019年 | 3027篇 |
2018年 | 4414篇 |
2017年 | 3247篇 |
2016年 | 3693篇 |
2015年 | 4144篇 |
2014年 | 5483篇 |
2013年 | 8506篇 |
2012年 | 11045篇 |
2011年 | 11560篇 |
2010年 | 7210篇 |
2009年 | 6514篇 |
2008年 | 10207篇 |
2007年 | 11157篇 |
2006年 | 10832篇 |
2005年 | 10240篇 |
2004年 | 9785篇 |
2003年 | 9169篇 |
2002年 | 8652篇 |
2001年 | 13427篇 |
2000年 | 13702篇 |
1999年 | 11499篇 |
1998年 | 3169篇 |
1997年 | 2871篇 |
1996年 | 2703篇 |
1995年 | 2617篇 |
1994年 | 2395篇 |
1992年 | 8339篇 |
1991年 | 8473篇 |
1990年 | 8280篇 |
1989年 | 8090篇 |
1988年 | 7336篇 |
1987年 | 7093篇 |
1986年 | 6742篇 |
1985年 | 6529篇 |
1984年 | 4776篇 |
1983年 | 4131篇 |
1982年 | 2486篇 |
1979年 | 4435篇 |
1978年 | 3231篇 |
1977年 | 2733篇 |
1976年 | 2506篇 |
1975年 | 2834篇 |
1974年 | 3359篇 |
1973年 | 3369篇 |
1972年 | 3119篇 |
1971年 | 2950篇 |
1970年 | 2839篇 |
1969年 | 2581篇 |
1968年 | 2538篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
1.
Michels Guido Horn Rudolf Helfen Andreas Hagendorff Andreas Jung Christian Hoffmann Beatrice Jaspers Natalie Kinkel Horst Greim Clemens-Alexander Knebel Fabian Bauersachs Johann Busch Hans-Jörg Kiefl Daniel Spiel Alexander O. Marx Gernot Dietrich Christoph F. 《Der Anaesthesist》2022,71(4):307-310
Die Anaesthesiologie - 相似文献
2.
Two Janus-associated kinase inhibitors (JAKi) (initially ruxolitinib and, more recently, fedratinib) have been approved as treatment options for patients who have intermediate-risk and high-risk myelofibrosis (MF), with pivotal trials demonstrating improvements in spleen volume, disease symptoms, and quality of life. At the same time, however, clinical trial experiences with JAKi agents in MF have demonstrated a high frequency of discontinuations because of adverse events or progressive disease. In addition, overall survival benefits and clinical and molecular predictors of response have not been established in this population, for which the disease burden is high and treatment options are limited. Consistently poor outcomes have been documented after JAKi discontinuation, with survival durations after ruxolitinib ranging from 11 to 16 months across several studies. To address such a high unmet therapeutic need, various non-JAKi agents are being actively explored (in combination with ruxolitinib in first-line or salvage settings and/or as monotherapy in JAKi-pretreated patients) in phase 3 clinical trials, including pelabresib (a bromodomain and extraterminal domain inhibitor), navitoclax (a B-cell lymphoma 2/B-cell lymphoma 2-xL inhibitor), parsaclisib (a phosphoinositide 3-kinase inhibitor), navtemadlin (formerly KRT-232; a murine double-minute chromosome 2 inhibitor), and imetelstat (a telomerase inhibitor). The breadth of data expected from these trials will provide insight into the ability of non-JAKi treatments to modify the natural history of MF. 相似文献
3.
4.
5.
6.
Mohid S Khan Thomas Walter Amy Buchanan-Hughes Emma Worthington Lucie Keeber Marion Feuilly Enrique Grande 《World journal of gastroenterology : WJG》2020,26(30):4537-4556
BACKGROUND Approximately 20% of patients with neuroendocrine tumours(NETs) develop carcinoid syndrome(CS),characterised by flushing and diarrhoea.Somatostatin analogues or telotristat can be used to control symptoms of CS through inhibition of serotonin secretion.Although CS is often the cause of diarrhoea among patients with gastroenteropancreatic NETs(GEP-NETs),other causes to consider include pancreatic enzyme insufficiency(PEI),bile acid malabsorption and small intestinal bacterial overgrowth.If other causes of diarrhoea unrelated to serotonin secretion are mistaken for CS diarrhoea,these treatments may be ineffective against the diarrhoea,risking detrimental effects to patient quality of life.AIM To identify and synthesise qualitative and quantitative evidence relating to the differential diagnosis of diarrhoea in patients with GEP-NETs.METHODS Electronic databases(MEDLINE,Embase and the Cochrane Library) were searched from inception to September 12,2018 using terms for NETs and diarrhoea.Congresses,systematic literature review bibliographies and included articles were also hand-searched.Any study designs and publication types were eligible for inclusion if relevant data on a cause(s) of diarrhoea in patients with GEP-NETs were reported.Studies were screened by two independent reviewers at abstract and full-text stages.Framework synthesis was adapted to synthesise quantitative and qualitative data.The definition of qualitative data was expanded to include all textual data in any section of relevant publications.RESULTS Forty-seven publications(44 studies) were included,comprising a variety of publication types,including observational studies,reviews,guidelines,case reports,interventional studies,and opinion pieces.Most reported on PEI on/after treatment with somatostatin analogs;9.5%-84% of patients with GEP-NETs had experienced steatorrhoea or confirmed PEI.Where reported,14.3%–50.7% of patients received pancreatic enzyme replacement therapy.Other causes of diarrhoea reported in patients with GEP-NETs included bile acid malabsorption(80%),small intestinal bacterial overgrowth(23.6%-62%),colitis(20%) and infection(7.1%).Diagnostic approaches included faecal elastase,breath tests,tauroselcholic(selenium-75) acid(Se HCAT) scan and stool culture,although evidence on the effectiveness or diagnostic accuracy of these approaches was limited.Assessment of patient history or diarrhoea characteristics was also reported as initial approaches for investigation.From the identified evidence,if diarrhoea is assumed to be CS diarrhoea,consequences include uncontrolled diarrhoea,malnutrition,and perceived ineffectiveness of CS treatment.Approaches for facilitating differential diagnosis of diarrhoea include improving patient and clinician awareness of non-CS causes and involvement of a multidisciplinary clinical team,including gastroenterologists.CONCLUSION Diarrhoea in GEP-NETs can be multifactorial with misdiagnosis leading to delayed patient recovery and inefficient resource use.This systematic literature review highlights gaps for further research on prevalence of non-CS diarrhoea and suitability of diagnostic approaches,to determine an effective algorithm for differential diagnosis of GEP-NET diarrhoea. 相似文献
7.
8.
9.